From: targetedonc.com In the first article of a 2-part series, Aditya Bardia, MD, MPH, leads a discussion on what factors influence sequencing treatment for patients with estrogen receptor positive advanced breast cancer. CASE SUMMARY A 62-year-old woman presented with a 6 cm right breast mass, which has been slowly growing for 1 year with palpable axillary nodes. Her liver function test …
NCCN Guidelines Endorse FES PET for Workup of Recurrent/Metastatic ER+ Breast Cancer
By: Caroline Seymour From: onclive.com The National Comprehensive Cancer Network (NCCN) Guidelines now recommend the use of 18F-Fluorestradiol (18F-FES; Cerianna) positron emission tomography (PET) in certain circumstances during the systemic staging workup for patients with recurrent or metastatic for estrogen receptor (ER)–positive breast cancer.1 This inclusion in the NCCN Guidelines comes after the publication of the October 2022 Appropriate Use …
Physicians Discuss Role of Elacestrant in ER+ Metastatic Breast Cancer
From: targetedonc.com During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants their reactions to the data from the phase 3 EMERALD study of elacestrant for patients with metastatic ER+ breast cancer. DISCUSSION QUESTIONS What are your reactions to the efficacy data from the phase 3 EMERALD study (NCT03778931) of elacestrant (Orserdu)? What are your reactions to …
Study of Immune ‘Neighborhoods’ Highlights Macrophages as Key Players in Invasive Breast Cancers
By: Asher Jones From: inside.upmc.com Most immunotherapies, which aim to boost T cell activity, work poorly in treating estrogen receptor-positive (ER+) breast cancer. Targeting a different type of immune cell called macrophages could be a more effective approach, suggests a comprehensive new analysis of invasive ER+ breast cancers led by University of Pittsburgh School of Medicine scientists. Published today in …
Overexpression of estrogen receptor gene linked to breast cancer risk in older women
By: Nick Paul Taylor From: scienceboard.net A first-of-its-kind mouse model of aging finds overexpression of the estrogen receptor 1 (ESR1) gene could increase the risk of estrogen receptor-positive breast cancer in postmenopausal women, according to research published December 1 in the American Journal of Pathology. During menopause, overall estrogen levels typically fall but in the breast levels of the estrogen …
Two simple biomarkers could differentiate which young women with ER+ breast cancer need chemotherapy
From: news-medical.net New research from Yale Cancer Center identified that two simple biomarkers, immune cells and estrogen receptor levels, could differentiate which young women with ER+ breast cancer need chemotherapy to improve their survival, and which only need a monthly injection to suppress ovarian function. The findings were recently published in npjBreast, Nature Partner Journals. Two large clinical trials, the …
Researchers uncover how breast cancer cells become resistant to therapy
By: Molly Chiu From: bcm.edu About one-fourth of recurrent estrogen receptor-positive (ER+) breast cancers lose ER expression, which renders them resistant to endocrine therapy and able to grow uncontrolled. A team of researchers at Baylor College of Medicine has investigated how these cells lose their ER, and in the current study published in the Proceedings of the National Academy of …
Androgen Receptor Agonist Active in Resistant ER+ Breast Cancer
By: Charles Bankhead From: medpagetoday.com Also: Combination targets uncommon form of advanced HER2-mutant disease A first-in-class androgen receptor (AR) agonist led to clinically meaningful objective response rates in patients with heavily treated estrogen receptor (ER)-positive breast cancer, a preliminary trial showed. Overall, 30% of patients obtained clinical benefit from either of two doses of enobosarm. Half of a small subgroup …
UH Researcher Finds a New Biomarker and Potential Drug Target for Breast Cancer
By: Laurie Fickman From: uh.edu After examining 398 proteins, a University of Houston College of Pharmacy researcher has found one that is an important biomarker predicting therapy outcome and a potential drug target in estrogen receptor-positive (ER+) breast cancer, which makes up approximately 80% of all breast cancers. The growth of ER+ breast cancer is stimulated by estrogen. “We found …
City of Hope researchers ID how most common breast cancer becomes resistant to treatment
Source: City of Hope From: eurekalert.org Understanding how tumors in patients with early-stage estrogen receptor positive breast cancer evolve to resist certain combination therapies can aid in the design of optimal drug strategies for people whose cancer potentially could be cured City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage …